-
Why do we offer a free initial review?
This is one of our most commonly asked questions – at the same time, we’re proud to offer a free…
-
Exciting news for inhaled lung fibrosis therapies
Last year we made a series of posts highlighting the opportunities and challenges of developing inhaled therapies for idiopathic pulmonary…
-
Did you know that TherapeutAix offer a project management service?
In this role, we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely…
-
New Innovative Partnerships?
Last year, Darcey Black, Director of Translational Science at TherapeutAix, together with colleagues, Gregor MacDonald from Lundbeck and Mo Alavijeh…
-
2022: A TherapeutAix Roundup
As the year draws to a close, we wanted to take a look back at our activities throughout 2022, reflecting…
-
What’s it like to work with us?
What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our…
-
One Project, Many Customers
In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets…
-
The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services…
-
Reflections from ECM2022, Copenhagen, July 2022
The Extracellular Matrix Pharmacology Symposium 2022, aka ECM2022, took place in Copenhagen a couple of weeks ago. The focus of…
-
Workshops reloaded
At TherapeutAix, we have a number of tools to support our clients. In addition to, for example, the MIRIADD approach…
